Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer. Co. uses drug conjugation technology to create therapeutics and companion imaging agents for personalized targeted therapies. Co.'s agents target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. Co. has rights to develop and commercialize PSMA-617 agents, including the drug candidate known as 177Lu-PSMA-617, a radioligand therapeutic. Co. is also developing a therapeutic approach that involves the re-targeting of potent immune cells, called chimeric antigen receptor T-cells to fight cancer. The ECYT average annual return 10 years is shown above.
The Average Annual Return on the ECYT average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ECYT average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ECYT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|